Juxtaposed against the background that nearly all randomized clinical trials of SGLT2 inhibitors enrolled high-risk groups (patients with or at high risk for cardiovascular disease and those with kidney disease or albuminuria), our results complement evidence from randomized clinical trials and suggest that the salutary association between SGLT2 inhibitors and the risk of mortality likely extends to lower risk groups, including those without cardiovascular disease, with eGFR greater than 60 mL/min/1.73 m2, and with no albuminuria or microalbuminuria. The gene discussed is SLC5A2; the disease is cardiovascular disorder.